Adaptive Biotechnologies (ADPT) still was trading more than 6% higher late in Friday's session, roughly halving its earlier advance after analysts at Goldman Sach raised their stock rating for the immuno-sequencing company to buy from neutral previously.
The Goldman analysts also increased their price target for Adaptive shares to $9 from their prior call of $8 per share.
Price: 8.24, Change: +0.48, Percent Change: +6.26